Interferon-β treatment of human disease

Current Opinion in Biotechnology

Volumn 6, Issue 6, 1995, Pages 688-691

  Alam, John J ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON;

ACUTE HEPATITIS; CHRONIC HEPATITIS; HUMAN; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SHORT SURVEY; VIRUS HEPATITIS;

ANIMAL; BIOTECHNOLOGY; CLINICAL TRIALS; HEPATITIS, VIRAL, HUMAN; HUMAN; INTERFERON-BETA; MULTIPLE SCLEROSIS; RECOMBINANT PROTEINS;

EID: 0028879657     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/0958-1669(95)80113-8     Document Type: Article

References (26)

1. Cytokine therapeutics: lessons from interferon α
2. α and β interferons and their receptor and their friends and relations
3. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins
4. Evidence for multiple binding sites for several components of human lymphoblastoid interferon-α
5. Use of a selectable marker regulated by alpha interferon to obtain mutations in the signaling pathway
6. Differential tyrosine phosphorylation of the IFNAR chain of the type I interferon receptor and of an associated surface protein in response to IFN-α and IFN-β
7. Multiple sclerosis and other demyelinating diseases
8. Intrathecally administered natural fibroblast interferon reduces exacerbations of multiple sclerosis: results of a multicenter double-blind study
9. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
10. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial
11. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial
12. The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis
13. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis
14. Basic research and clinical applications of natural interferon-β
15. Treatment of chronic non-A, non-B hepatitis with human interferon-β, a randomized controlled trial with different durations [in Japanese]
16. A pilot study of long-term weekly interferon-β administration for chronic hepatitis B
17. A comparative study between daily and weekly injections of interferon-β in the treatment of chronic hepatitis B
18. Resolution of acute hepatitis C after therapy with natural beta interferon
19. Interferon therapy for acute postransfusion non-A, non-B hepatitis: response with respect to anti-hepatitis C virus antibody status
20. Effects of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. Japan acute hepatitis cooperative study group
21. Intramuscular natural beta interferon in the treatment of chronic hepatitis B: a multicentre trial. Italian hepatitis B study group
22. Recombinant alpha-interferon is superior to natural beta-interferon in the treatment of chronic hepatitis C
23. Human fibroblastic beta-interferon vs. alpha lymphoblastoid interferon in chronic hepatitis C
24. Alpha but not beta interferon (IFN) is useful in NA, NB chronic active hepatitis (CAH): final report of a comparative, prospective, randomized study
25. Double-blind, randomized clinical trial on the effect of interferon-beta in the treatment of condylomata acuminata
26. Intramuscular interferon-beta treatment of cervical intraepithelial neoplasia II associated with human papillomavirus infection